Discounted Cash Flow
West Pharmaceutical Services Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $1.5b | $143.6m | $49.2m | 9.5% | $1.96 |
| 2017 | $1.6b (6.0%) | $150.7m (4.9%) | $132.5m (169.3%) | 9.4% (-1.0%) | $2.04 (4.1%) |
| 2018 | $1.7b (7.4%) | $206.9m (37.3%) | $183.9m (38.8%) | 12.0% (27.8%) | $2.80 (37.3%) |
| 2019 | $1.8b (7.1%) | $241.7m (16.8%) | $240.8m (30.9%) | 13.1% (9.0%) | $3.27 (16.8%) |
| 2020 | $2.1b (16.7%) | $346.2m (43.2%) | $298.1m (23.8%) | 16.1% (22.8%) | $4.68 (43.1%) |
| 2021 | $2.8b (31.9%) | $661.8m (91.2%) | $330.6m (10.9%) | 23.4% (44.9%) | $8.89 (90.0%) |
| 2022 | $2.9b (2.0%) | $585.9m (-11.5%) | $439.4m (32.9%) | 20.3% (-13.2%) | $7.87 (-11.5%) |
| 2023 | $2.9b (2.2%) | $593.4m (1.3%) | $414.5m (-5.7%) | 20.1% (-0.9%) | $7.98 (1.4%) |
| 2024 | $2.9b (-1.9%) | $492.7m (-17.0%) | $276.4m (-33.3%) | 17.0% (-15.3%) | $6.75 (-15.4%) |
| 2025 | $3.1b (6.3%) | $493.7m (0.2%) | $468.9m (69.6%) | 16.1% (-5.7%) | $6.83 (1.2%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.